CO6842016A2 - Terapia de combinación que comprende un inhibidor de cdk4/6 y un inhibidor de pi3k para el uso en el tratamiento de cáncer - Google Patents

Terapia de combinación que comprende un inhibidor de cdk4/6 y un inhibidor de pi3k para el uso en el tratamiento de cáncer

Info

Publication number: CO6842016A2
Authority: CO; Colombia
Prior art keywords: inhibitor; cdk4; cancer; treatment; combination therapy
Prior art date: 2011-07-01

Application number

CO13297787A

Other languages

English (en)

Inventor

Sunkyu Kim

Shivang Doshi

Kristy Haas

Steven Kovats

Alah Xizhong Huang

Yan Chen

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-07-01

Filing date

2013-12-20

Publication date

2014-01-20

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46513871&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6842016(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2013-12-20 Application filed by Novartis Ag filed Critical Novartis Ag

2014-01-20 Publication of CO6842016A2 publication Critical patent/CO6842016A2/es

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Hematology (AREA)
Oncology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

CO13297787A 2011-07-01 2013-12-20 Terapia de combinación que comprende un inhibidor de cdk4/6 y un inhibidor de pi3k para el uso en el tratamiento de cáncer CO6842016A2 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201161503642P	2011-07-01	2011-07-01

Publications (1)

Publication Number	Publication Date
CO6842016A2 true CO6842016A2 (es)	2014-01-20

Family

ID=46513871

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CO13297787A CO6842016A2 (es)	2011-07-01	2013-12-20	Terapia de combinación que comprende un inhibidor de cdk4/6 y un inhibidor de pi3k para el uso en el tratamiento de cáncer

Country Status (23)

Country	Link
US (2)	US9271988B2 (es)
EP (1)	EP2726074B1 (es)
JP (2)	JP5832647B2 (es)
KR (1)	KR20140040770A (es)
CN (1)	CN103635189B (es)
AU (3)	AU2012279117A1 (es)
BR (1)	BR112013033940A2 (es)
CA (1)	CA2840754A1 (es)
CL (1)	CL2013003805A1 (es)
CO (1)	CO6842016A2 (es)
EA (1)	EA030465B1 (es)
ES (1)	ES2676180T3 (es)
GT (1)	GT201300320A (es)
IL (1)	IL229876B (es)
MA (1)	MA35210B1 (es)
MX (1)	MX359406B (es)
MY (1)	MY161237A (es)
PE (1)	PE20141381A1 (es)
PH (1)	PH12013502697A1 (es)
TN (1)	TN2013000508A1 (es)
UA (1)	UA114178C2 (es)
WO (1)	WO2013006532A1 (es)
ZA (1)	ZA201309241B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8193182B2 (en)	2008-01-04	2012-06-05	Intellikine, Inc.	Substituted isoquinolin-1(2H)-ones, and methods of use thereof
DK2240451T3 (da)	2008-01-04	2017-11-20	Intellikine Llc	Isoquinolinonderivater substitueret med en purin, der er anvendelig som pi3k-inhibitorer
PE20180318A1 (es)	2011-01-10	2018-02-09	Infinity Pharmaceuticals Inc	Procedimiento para preparar isoquinolinonas y formas solidas de isoquinolinonas
AU2012279117A1 (en) *	2011-07-01	2014-01-09	Novartis Ag	Combination therapy comprising a CDK4/6 inhibitor and a PI3K inhibitor for use in the treatment of cancer
US20150051252A1 (en) *	2012-03-30	2015-02-19	Xizhong Huang	Compounds for use in the treatment of neuroblastoma, ewing's sarcoma or rhabdomyosarcoma
US8828998B2 (en)	2012-06-25	2014-09-09	Infinity Pharmaceuticals, Inc.	Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
HK1213044A1 (zh)	2012-08-03	2016-06-24	Foundation Medicine, Inc.	人乳头瘤病毒作为肿瘤预後的预测因子
LT2914296T (lt)	2012-11-01	2018-09-25	Infinity Pharmaceuticals, Inc.	Vėžio gydymas, panaudojant p13 kinazės izoformos moduliatorius
EP2742940B1 (en)	2012-12-13	2017-07-26	IP Gesellschaft für Management mbH	Fumarate salt of (R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-l-aza-bicyclo-[2.2.2]octane for adminstration once daily, twice daily or thrice daily
EP2967050A4 (en)	2013-03-15	2016-09-28	G1 Therapeutics Inc	HIGH-ACTIVE ANTINEOPLASTIC AND ANTIPROLIFERATIVE AGENTS
EP2968291B1 (en)	2013-03-15	2025-04-16	Pharmacosmos Holding A/S	Hspc-sparing treatments for rb-positive abnormal cellular proliferation
ES2900829T3 (es) *	2013-08-14	2022-03-18	Novartis Ag	Terapia combinada para el tratamiento del cáncer
US20150320754A1 (en)	2014-04-16	2015-11-12	Infinity Pharmaceuticals, Inc.	Combination therapies
US20150320755A1 (en)	2014-04-16	2015-11-12	Infinity Pharmaceuticals, Inc.	Combination therapies
US9717735B2 (en)	2014-04-17	2017-08-01	G1 Therapeutics, Inc.	Tricyclic lactams for use in HSPC-sparing treatments for RB-positive abnormal cellular proliferation
WO2016040858A1 (en) *	2014-09-12	2016-03-17	G1 Therapeutics, Inc.	Combinations and dosing regimes to treat rb-positive tumors
WO2016040848A1 (en)	2014-09-12	2016-03-17	G1 Therapeutics, Inc.	Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
EP4585597A1 (en)	2015-07-02	2025-07-16	F. Hoffmann-La Roche AG	Benzoxazepin oxazolidinone compounds and methods of use
CN107995911B (zh)	2015-07-02	2020-08-04	豪夫迈·罗氏有限公司	苯并氧氮杂*噁唑烷酮化合物及其使用方法
EP3340986A1 (en) *	2015-08-28	2018-07-04	Novartis AG	A pharmaceutical combination comprising the pi3k inhibitor alpelisib and the cdk4/6 inhibitor ribociclib, and the use thereof in the treatment/prevention of cancer
WO2017172734A1 (en)	2016-03-29	2017-10-05	Mayo Foundation For Medical Education And Research	Treating cancer metastasis
UA125216C2 (uk)	2016-06-24	2022-02-02	Інфініті Фармасьютікалз, Інк.	Комбінована терапія
WO2018017410A1 (en)	2016-07-22	2018-01-25	Eli Lilly And Company	Combination therapy of abemaciclib and a pi3 kinase/mtor dual inhibitor for use in the treatment of breast cancer
WO2018081211A1 (en) *	2016-10-26	2018-05-03	Li George Y	Deuterated 7-cyclopentyl-n, n-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7h-pyrrolo[2,3-d]pyrimdine-6-carboxamide
KR20240023677A (ko)	2016-12-05	2024-02-22	쥐원 쎄라퓨틱스, 인크.	화학요법 레지멘 동안의 면역 반응의 보존
US11395821B2 (en)	2017-01-30	2022-07-26	G1 Therapeutics, Inc.	Treatment of EGFR-driven cancer with fewer side effects
WO2019136451A1 (en)	2018-01-08	2019-07-11	G1 Therapeutics, Inc.	G1t38 superior dosage regimes
KR20210031852A (ko) *	2018-03-05	2021-03-23	클리니쿰 레히츠 데어 이자르 데어 테크니쉔 우니베르지테트 뮌헨	종양 세포 붕괴성 아데노바이러스와 cdk4/6 억제제의 조합물에 의한 종양의 치료
CN111184863B (zh) *	2018-11-15	2023-06-16	江苏恒瑞医药股份有限公司	酪氨酸激酶抑制剂、cdk4/6抑制剂、serd联合在制备治疗肿瘤的药物中的用途
US10988479B1 (en)	2020-06-15	2021-04-27	G1 Therapeutics, Inc.	Morphic forms of trilaciclib and methods of manufacture thereof
CN117597126A (zh) *	2021-07-06	2024-02-23	国立癌症中心	包含cdk4/6抑制剂和三环类抗抑郁剂的用于预防或治疗癌症的药物组合物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7196078B2 (en) *	2002-09-04	2007-03-27	Schering Corpoartion	Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors
US8673924B2 (en) *	2002-09-04	2014-03-18	Merck Sharp & Dohme Corp.	Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
US7423148B2 (en)	2002-11-21	2008-09-09	Chiron Corporation	Small molecule PI 3-kinase inhibitors and methods of their use
TW200519106A (en)	2003-05-02	2005-06-16	Novartis Ag	Organic compounds
GB0510390D0 (en)	2005-05-20	2005-06-29	Novartis Ag	Organic compounds
JO2660B1 (en) *	2006-01-20	2012-06-17	نوفارتيس ايه جي	Pi-3 inhibitors and methods of use
TWI398252B (zh)	2006-05-26	2013-06-11	Novartis Ag	吡咯并嘧啶化合物及其用途
AR070127A1 (es)	2008-01-11	2010-03-17	Novartis Ag	Pirrolo - pirimidinas y pirrolo -piridinas
CA2714177A1 (en)	2008-02-06	2009-08-13	Novartis Ag	Pyrrolo [2,3-d] pyridines and use thereof as tyrosine kinase inhibitors
CN102186856B (zh) *	2008-08-22	2014-09-24	诺华股份有限公司	作为cdk抑制剂的吡咯并嘧啶化合物
UA104147C2 (uk) *	2008-09-10	2014-01-10	Новартис Аг	Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
UY33227A (es)	2010-02-19	2011-09-30	Novartis Ag	Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
RU2015150728A (ru)	2010-10-01	2019-01-15	Новартис Аг	Способ получения пиримидиновых производных
AR083797A1 (es)	2010-11-10	2013-03-20	Novartis Ag	Succinato de dimetil-amida del acido 7-ciclopentil-2-(5-piperazin-1-il-piridin-2-il-amino)-7h-pirrolo-[2,3-d]pirimidin-6-carboxilico, proceso para prepararla, intermediarios de dicha sintesis y proceso de preparacion de los mismos
AU2012279117A1 (en) *	2011-07-01	2014-01-09	Novartis Ag	Combination therapy comprising a CDK4/6 inhibitor and a PI3K inhibitor for use in the treatment of cancer
EP2925365A1 (en) *	2012-11-28	2015-10-07	Novartis AG	Combination therapy

2012
- 2012-07-02 AU AU2012279117A patent/AU2012279117A1/en not_active Abandoned
- 2012-07-02 BR BR112013033940A patent/BR112013033940A2/pt not_active IP Right Cessation
- 2012-07-02 EA EA201490194A patent/EA030465B1/ru not_active IP Right Cessation
- 2012-07-02 EP EP12735408.2A patent/EP2726074B1/en active Active
- 2012-07-02 UA UAA201314209A patent/UA114178C2/uk unknown
- 2012-07-02 KR KR1020137034740A patent/KR20140040770A/ko not_active Abandoned
- 2012-07-02 CN CN201280032544.5A patent/CN103635189B/zh not_active Expired - Fee Related
- 2012-07-02 MY MYPI2013004386A patent/MY161237A/en unknown
- 2012-07-02 CA CA2840754A patent/CA2840754A1/en not_active Abandoned
- 2012-07-02 PE PE2013002911A patent/PE20141381A1/es active IP Right Grant
- 2012-07-02 JP JP2014519218A patent/JP5832647B2/ja not_active Expired - Fee Related
- 2012-07-02 WO PCT/US2012/045199 patent/WO2013006532A1/en not_active Ceased
- 2012-07-02 MX MX2013015370A patent/MX359406B/es active IP Right Grant
- 2012-07-02 US US14/124,753 patent/US9271988B2/en active Active
- 2012-07-02 ES ES12735408.2T patent/ES2676180T3/es active Active
- 2012-07-02 PH PH1/2013/502697A patent/PH12013502697A1/en unknown
2013
- 2013-12-06 TN TNP2013000508A patent/TN2013000508A1/fr unknown
- 2013-12-09 IL IL229876A patent/IL229876B/en active IP Right Grant
- 2013-12-09 ZA ZA2013/09241A patent/ZA201309241B/en unknown
- 2013-12-20 CO CO13297787A patent/CO6842016A2/es unknown
- 2013-12-20 GT GT201300320A patent/GT201300320A/es unknown
- 2013-12-26 MA MA36616A patent/MA35210B1/fr unknown
- 2013-12-31 CL CL2013003805A patent/CL2013003805A1/es unknown
2015
- 2015-08-17 JP JP2015160531A patent/JP2016027043A/ja active Pending
2016
- 2016-01-22 US US15/003,860 patent/US10010552B2/en active Active
- 2016-04-08 AU AU2016202213A patent/AU2016202213A1/en not_active Abandoned
2017
- 2017-09-21 AU AU2017232162A patent/AU2017232162B2/en not_active Ceased

Also Published As

Publication number	Publication date
US20160136171A1 (en)	2016-05-19
US10010552B2 (en)	2018-07-03
AU2016202213A1 (en)	2016-05-05
US9271988B2 (en)	2016-03-01
CN103635189B (zh)	2016-05-04
AU2012279117A1 (en)	2014-01-09
EA201490194A1 (ru)	2014-04-30
MX2013015370A (es)	2014-02-11
IL229876B (en)	2018-10-31
EP2726074B1 (en)	2018-04-04
CA2840754A1 (en)	2013-01-10
PH12013502697A1 (en)	2014-02-10
AU2017232162A1 (en)	2017-10-12
TN2013000508A1 (en)	2015-03-30
AU2017232162B2 (en)	2019-03-07
ZA201309241B (en)	2014-08-27
CL2013003805A1 (es)	2014-08-08
BR112013033940A2 (pt)	2017-02-14
MA35210B1 (fr)	2014-06-02
JP2014518279A (ja)	2014-07-28
GT201300320A (es)	2016-03-01
EP2726074A1 (en)	2014-05-07
ES2676180T3 (es)	2018-07-17
WO2013006532A1 (en)	2013-01-10
KR20140040770A (ko)	2014-04-03
MY161237A (en)	2017-04-14
PE20141381A1 (es)	2014-10-21
EA030465B1 (ru)	2018-08-31
MX359406B (es)	2018-09-27
UA114178C2 (uk)	2017-05-10
CN103635189A (zh)	2014-03-12
US20140107114A1 (en)	2014-04-17
JP2016027043A (ja)	2016-02-18
JP5832647B2 (ja)	2015-12-16

Publication	Publication Date	Title
CO6842016A2 (es)	2014-01-20	Terapia de combinación que comprende un inhibidor de cdk4/6 y un inhibidor de pi3k para el uso en el tratamiento de cáncer
BR112012004970A2 (pt)	2016-04-12	inibidores de jak2 e seu uso para o tratamento de doenças mieloproliferativas e câncer
SMT201600430B (it)	2017-01-10	Inibitori di chinasi e loro uso nel trattamento del cancro
BRPI1013698A2 (pt)	2016-04-26	métodos para tratamento com o uso de terapia de combinação
CO6900118A2 (es)	2014-03-20	Métodos para tratar el cancer por el uso de antagonistas de unión al eje pd-1e inhibidores de mek
CL2013001093A1 (es)	2013-09-27	Compuestos triciclicos inhibidores de la quinasa pi3 (pi3k); composicion farmaceutica que los comprende; metodo para tratar el cancer; y su uso para el tratamiento del cancer .
CL2014001062A1 (es)	2014-10-10	Metodo para tratar tumores del estroma gastrointestinal que comprende el uso de un inhibidor de c-hit y un inhibidor de pi3k o fgfr y combinacion que comprende a los compuestos.
IL238400A (en)	2017-07-31	Triazulophyrazines as brd4 inhibitors for use in cancer treatment
CO6930363A2 (es)	2014-04-28	Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
IL232256A0 (en)	2014-06-30	Novel purine derivatives and their use in the treatment of disease
PL2694485T3 (pl)	2018-04-30	Kombinacja związku inhibitora akt i wemurafenibu do zastosowania w leczeniach terapeutycznych
CL2012003281A1 (es)	2013-05-17	Uso de compuestos específicos estimuladores y/o activadores de sgc; formulacion farmaceutica que comprende dichos compuestos; kit que comprende los compuestos, y uso para la prevencion y/o tratamiento de la esclerosis sistematica.
CO6811867A2 (es)	2013-12-16	Cannabinoides para uso en el tratamiento del dolor neuropático
GB201115711D0 (en)	2011-10-26	Phyto-cannabinoids for use in the treatment of cancer
CO6821936A2 (es)	2013-12-31	Derivados de quinazolina en combinación con otros tratamientos terapeúticos para neoplasias hematológicas malignas y ciertas otras condiciones
BR112014006419A2 (pt)	2018-08-07	métodos para tratar um paciente com câncer, kit e artigo
BR112014010739A2 (pt)	2017-04-25	agentes terapêuticos e uso dos mesmos
CL2015001530A1 (es)	2016-03-28	Uso de inhibidores de telomerasa para el tratamiento de desórdenes mieloproliferativos y neoplasias mieloproliferativas
CL2013001324A1 (es)	2014-05-16	Kit que comprende ec145 y uno o mas agentes quimioterapéuticos adicionales; uso para tratar un cancer.
BR112015002706A2 (pt)	2017-08-08	niclosamida e seus derivados para uso no tratamento de tumores sólidos
BR112013034055A2 (pt)	2017-02-07	alcaftadina para uso no tratamento de urticária
BR112012030927A2 (pt)	2017-12-05	fosfaplatinas e seu uso para o tratamento de cânceres
HRP20171280T1 (hr)	2018-01-12	Pirazolilgvanidinski inhibitori f1f0-atpaze i njihova upotreba u terapiji
BR112013014198A2 (pt)	2016-09-13	composições compreendendo um inibidor de pi3k e um inibidor de mek e seu uso para o tratamento de câncer
BR112014007150A2 (pt)	2017-04-04	artigos abrasivos de redução de ruído